Novartis drug is already approved. They are currently focusing on distribution and undertaking other studies to increase market share in the current treatable population. As I understand, Novartis are still interested in having their treatment offered earlier in the treatment process, which may open the door for Veyonda at some point in the future. Looks like a interesting 3rd and 4th quarter for holders.
Novartis drug is already approved. They are currently focusing...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.5¢ | $9.527K | 82.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 198945 | 9 |
View Market Depth
| Last trade - 14.58pm 13/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |